Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study on Resectable or Borderline Resectable Pancreas Adenocarcinoma Preoperative Treatment with Chemotherapy and Carbon Ions Radiation Therapy (hadrontherapy)

NCT03822936 is registered in ClinicalTrials.gov with CNAO National Center of Oncological Hadrontherapy as lead sponsor.

NCT NCT03822936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03822936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study on Resectable or Borderline Resectable Pancreas Adenocarcinoma Preoperative Treatment with Chemotherapy and Carbon Ions Radiation Therapy (hadrontherapy)
Lead sponsor
CNAO National Center of Oncological Hadrontherapy
Phase
Phase 2
Overall status
Terminated
Start date
February 8, 2018
Completion date
February 10, 2025
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of pancreas, pancreas adenocarcinoma, resectable pancreatic cancer